Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Last trade$32.25
Day change-$0.19 (-0.59%)
Day range$31.38 – $32.61
Volume97,662
Market cap$2.30B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for PHVS.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for PHVS.
Recent news
Company coverage with links to the original publishers.
Pharvaris (PHVS) has gained 20.3% over the past four weeks and Wall Street analysts project a mean upside of 79.4% with a price target of $59.85. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets alone should not drive investment decisions, as analysts often set overly optimistic targets due to business incentives.
Pharvaris announced that Phase 3 RAPIDe-3 trial results for deucrictibant IR, an oral bradykinin B2 receptor antagonist for on-demand treatment of hereditary angioedema (HAE) attacks, were published in The Lancet. The drug achieved symptom relief in 1.28 hours and complete resolution in 11.95 hours, met its primary endpoint and all 11 secondary endpoints, and showed a well-tolerated safety profile. An NDA with the FDA (PDUFA target date April 23, 2027) and MAA with the EMA are currently under regulatory review.
Pharvaris-funded analysis of real-world HAE management reveals significant gaps between guideline-recommended care and clinical practice. Study of 225 physicians and 279 patients identified key barriers to treatment adherence, including treatment burden, route of administration, and patient perception of attack severity. Findings highlight unmet needs and suggest oral daily treatment is preferred over injectable options, supporting Pharvaris' development of oral bradykinin B2 receptor antagonists.
Pharvaris announced publication of a qualitative study assessing disease burden in AAE-C1INH patients and validating patient-reported outcome measures. The study findings informed the design of the ongoing Phase 3 CREAATE trial investigating deucrictibant for prophylaxis and on-demand treatment of AAE-C1INH attacks. Results demonstrated significant multifaceted disease burden with frequent painful attacks disrupting daily life, and validated the use of established PRO instruments for measuring treatment benefits.
Pharvaris director Johannes Schikan sold 37,600 shares worth $1.3 million in late June 2026, representing 10.66% of his direct holdings. The sale occurred under a Rule 10b5-1 trading plan following a 96.5% one-year stock price appreciation. Shortly after, the FDA accepted the company's New Drug Application for its lead drug deucrictibant for hereditary angioedema treatment, though the stock has remained relatively flat since the announcement.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.